In general, early HR positive, i.e., estrogen receptor (ER) and/or progesterone receptor (PR) positive, IBC frequently responds to endocrine therapy, whereas HER2 positive IBC benefits from anti-HER2 therapy. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.